{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:21Z","timestamp":1794047481240,"version":"4.8.0"},"reference-count":30,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"12","license":[{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>The aim of this study was to evaluate the efficacy and safety of flumatinib in later-line treatment of Chinese patients with Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia ((CP-CML) previously treated with tyrosine kinase inhibitors (TKI). Patients with CML-CP were evaluated for probabilities of responses, including complete hematologic response (CHR), cytogenetic response, and molecular response (MR), and adverse events after the later-line flumatinib therapy. Of 336 enrolled patients with a median age 50 years, the median duration of treatment with flumatinib was 11.04 months (range, 2-25.23). Patients who achieved clinical responses at baseline showed maintenance of CHR, complete cytogenetic response (CCyR) or 2-log molecular response (MR2), major molecular response (MMR), and 4-log molecular response or deep molecular response (MR4\/DMR) in 100%, 98.9%, 98.6%, and 92.9% of patients, respectively. CHR, CCyR\/MR2, MMR, and MR4\/DMR were achieved in 86.4%, 52.7%, 49.6%, and 23.5% of patients, respectively, who lacked the respective clinical responses at baseline. The patients without response at baseline, treated with flumatinib as a second-line TKI, having no resistance to prior TKI or only resistance to imatinib, with response to last TKI, and with BCR::ABL \u226410% had higher CCyR\/MR2, MMR, or MR4\/DMR rates. The adverse events observed during the later-line flumatinib treatment were tolerable and consistent with those reported with the first-line therapy. Flumatinib was effective and safe in patients who were resistant or intolerant to other TKI. In particular, second-line flumatinib treatment induced high response rates and was more beneficial to patients without previous second-generation TKI resistance, thus serving as a probable treatment option for these patients.<\/jats:p>","DOI":"10.3324\/haematol.2023.284892","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T04:38:26Z","timestamp":1719463106000},"page":"3965-3974","source":"Crossref","is-referenced-by-count":7,"title":["Safety and efficacy of flumatinib as later-line therapy in patients with chronic myeloid leukemia"],"prefix":"10.3324","volume":"109","author":[{"given":"Yunfan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuntao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianda","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuliang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilinazi","family":"Abulaiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luoming","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanling","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingcheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,6,27]]},"reference":[{"key":"69811","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Baccarani M, Silver RT. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020; 34(4):966-984.","DOI":"10.1038\/s41375-020-0776-2"},{"key":"69812","doi-asserted-by":"crossref","unstructured":"Welch HG, Kramer BS, Black WC. Epidemiologic signatures in cancer. N Engl J Med. 2019; 381(14):1378-1386.","DOI":"10.1056\/NEJMsr1905447"},{"key":"69813","doi-asserted-by":"crossref","unstructured":"Bower H, Bj\u00f6rkholm M, Dickman PW, H\u00f6glund M, Lambert PC, Andersson TM-L. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016; 34(24):2851-2857.","DOI":"10.1200\/JCO.2015.66.2866"},{"key":"69814","doi-asserted-by":"crossref","unstructured":"Breccia M, Efficace F, Colafigli G. Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice. Expert Rev Hematol. 2020; 13(12):1311-1318.","DOI":"10.1080\/17474086.2021.1852924"},{"key":"69815","doi-asserted-by":"crossref","unstructured":"Deininger MW, Shah NP, Altman JK. Chronic myeloid leukemia, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020; 18(10):1385-1415.","DOI":"10.6004\/jnccn.2020.0047"},{"key":"69816","doi-asserted-by":"crossref","unstructured":"E\u015fkazan AE. Asciminib in chronic myeloid leukemia: many questions still remain to be answered. Blood Cancer J. 2021; 11(4):81.","DOI":"10.1038\/s41408-021-00475-7"},{"key":"69817","doi-asserted-by":"crossref","unstructured":"Gambacorti-Passerini C, Aroldi A, Cordani N, Piazza R. Chronic myeloid leukemia: second-line drugs of choice. Am J Hematol. 2016; 91(1):67-75.","DOI":"10.1002\/ajh.24247"},{"key":"69818","doi-asserted-by":"crossref","unstructured":"Cortes J, Lang F. Third-line therapy for chronic myeloid leukemia: current status and future directions. J Hematol Oncol. 2021; 14(1):44.","DOI":"10.1186\/s13045-021-01055-9"},{"key":"69819","doi-asserted-by":"crossref","unstructured":"Cortes J, Rea D, Lipton JH. Treatment-free remission with first- and second-generation tyrosine kinase inhibitors. Am J Hematol. 2019; 94(3):346-357.","DOI":"10.1002\/ajh.25342"},{"key":"69820","doi-asserted-by":"crossref","unstructured":"Luo H, Quan H, Xie C, Xu Y, Fu L, Lou L. HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance. Leukemia. 2010; 24(10):1807-1809.","DOI":"10.1038\/leu.2010.169"},{"key":"69821","doi-asserted-by":"crossref","unstructured":"Wang W, Sun Q. Novel targeted drugs approved by the NMPA and FDA in 2019. Signal Transduct Target Ther. 2020; 5(1):65.","DOI":"10.1038\/s41392-020-0164-4"},{"key":"69822","unstructured":"Zou X, Yang Z, Wang Y, Li W. A patient of chronic myeloid leukemia with BCR::ABL1 F317L mutation successfully treated with flumatinib. J Clin Intern Med. 2022; 39(10):682-683."},{"key":"69823","doi-asserted-by":"crossref","unstructured":"Zhang L, Meng L, Liu B. Flumatinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: a phase III, randomized, open-label, multi-center FESTnd study. Clin Cancer Res. 2021; 27(1):70-77.","DOI":"10.1158\/1078-0432.CCR-20-1600"},{"key":"69824","doi-asserted-by":"crossref","unstructured":"Zhao J, Quan H, Xu Y, Kong X, Jin L, Lou L. Flumatinib, a selective inhibitor of BCR-ABL\/PDGFR\/KIT, effectively overcomes drug resistance of certain KIT mutants. Cancer Sci. 2014; 105(1):117-125.","DOI":"10.1111\/cas.12320"},{"key":"69825","doi-asserted-by":"crossref","unstructured":"Yang M, Xi Q, Jia W, Wang X. Structure-based analysis and biological characterization of imatinib derivatives reveal insights towards the inhibition of wild-type BCR-ABL and its mutants. Bioorg Med Chem Lett. 2019; 29(24):126758.","DOI":"10.1016\/j.bmcl.2019.126758"},{"key":"69826","doi-asserted-by":"crossref","unstructured":"Huang X, Jiang Q, Hu J. Four-year follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving dasatinib: efficacy and safety. Front Med. 2019; 13(3):344-353.","DOI":"10.1007\/s11684-018-0639-7"},{"key":"69827","doi-asserted-by":"crossref","unstructured":"Kantarjian HM, Giles FJ, Bhalla KN. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011; 117(4):1141-1145.","DOI":"10.1182\/blood-2010-03-277152"},{"key":"69828","doi-asserted-by":"crossref","unstructured":"Shah NP, Guilhot F, Cortes JE. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood. 2014; 123(15):2317-2324.","DOI":"10.1182\/blood-2013-10-532341"},{"key":"69829","doi-asserted-by":"crossref","unstructured":"Cortes J, Quintas-Cardama A, Jabbour E. The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?. Clin Lymphoma Myeloma Leuk. 2011; 11(5):421-426.","DOI":"10.1016\/j.clml.2011.06.009"},{"key":"69830","doi-asserted-by":"crossref","unstructured":"Giles FJ, Abruzzese E, Rosti G. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia. 2010; 24(7):1299-1301.","DOI":"10.1038\/leu.2010.110"},{"key":"69831","doi-asserted-by":"crossref","unstructured":"Garg RJ, Kantarjian H, O\u2019Brien S. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood. 2009; 114(20):4361-4368.","DOI":"10.1182\/blood-2009-05-221531"},{"key":"69832","doi-asserted-by":"crossref","unstructured":"Ibrahim AR, Paliompeis C, Bua M. Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy. Blood. 2010; 116(25):5497-5500.","DOI":"10.1182\/blood-2010-06-291922"},{"key":"69833","doi-asserted-by":"crossref","unstructured":"Russo Rossi A, Breccia M, Abruzzese E. Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors. Haematologica. 2013; 98(3):399-403.","DOI":"10.3324\/haematol.2012.064337"},{"key":"69834","doi-asserted-by":"crossref","unstructured":"Khoury HJ, Cortes JE, Kantarjian HM. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and\/or nilotinib therapy failure. Blood. 2012; 119(15):3403-3412.","DOI":"10.1182\/blood-2011-11-390120"},{"key":"69835","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Gambacorti-Passerini C, Abboud C. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. Leukemia. 2020; 34(8):2125-2137.","DOI":"10.1038\/s41375-020-0915-9"},{"key":"69836","doi-asserted-by":"crossref","unstructured":"Kantarjian HM, Jabbour E, Deininger M. Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia. Am J Hematol. 2022; 97(11):1419-1426.","DOI":"10.1002\/ajh.26686"},{"key":"69837","doi-asserted-by":"crossref","unstructured":"Jiang Q, Li Z, Qin Y. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1\/2 trial. J Hematol Oncol. 2022; 15(1):113.","DOI":"10.1186\/s13045-022-01334-z"},{"key":"69838","doi-asserted-by":"crossref","unstructured":"Kantarjian HM, Hughes TP, Larson RA. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021; 35(2):440-453.","DOI":"10.1038\/s41375-020-01111-2"},{"key":"69839","doi-asserted-by":"crossref","unstructured":"Sakurai M, Kikuchi T, Karigane D. Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia. Int J Hematol. 2019; 109(3):292-298.","DOI":"10.1007\/s12185-019-02596-z"},{"key":"69840","doi-asserted-by":"crossref","unstructured":"Cortes JE, Gambacorti-Passerini C, Kim D-W. Effects of bosutinib treatment on renal function in patients with Philadelphia chromosome-positive leukemias. Clin Lymphoma Myeloma Leuk. 2017; 17(10):684-695.","DOI":"10.1016\/j.clml.2017.06.001"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284892\/77241","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284892\/77834","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11666\/77241","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:06:46Z","timestamp":1794046006000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,27]]},"references-count":30,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284892","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,27]]}}}